Уноси

• Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation (2017-08)

  P. Vella Bonanno, M. Ermisch, B. Godman, A. Martin, J. Van Den Bergh, L. Bezmelnitsyna, A. Bucsics, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Diogene, I. Eriksson, J. Furst, M. Gad, I. Greičiute-Kuprijanov, M. van der Graff, J. Gulbinovic, J. Jones, R. Joppi, M. Kalaba, O. Laius, I. Langner, I. Mardare, V. Marković Peković, E. Magnusson, O. Melien, D. Meshkov, G. Petrova, G. Selke, C. Sermet, S. Simoens, A. Schuurman, R. Ramos, J. Rodrigues, C. Zara, E. Zebedin-Brandl, A. Haycox, Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation, Frontiers in Pharmacology, Vol. 8, pp. 1 - 13, Aug, 2017

• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

  R. Malmstrom, E. Digene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, S. Campbell, A. Ferrario, A. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffman, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Marković Peković, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulnay, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Frontiers in Pharmacology, Vol. 4, pp. 1 - 31, May, 2013

• Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future (2015-05)

  B. Godman, M. Wilcock, A. Martin, S. Bryson, C. Baumgartel, T. Bochenek, W. de Bruyn, L. Sović-Brkičić, M. D'Agata, A. Fogele, A. Coma Fuste, J. Fraeyman, J. Furst, K. Garuoliene, H. Herholz, M. Hoffman, S. Jayathissa, H. Kwon, I. Langner, M. Kalaba, E. Magnusson, E. Anderse Karlssen, O. Laius, V. Marković Peković, E. Magnusson, S. McTaggart, H. Pedersen, J. Piessnegger, A. Ringerud, G. Selke, C. Sermet, K. Schiffers, P. Skiold, D. Tomek, A. Viksna, A. Vitry, C. Zara, R. Malmstrom, Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future, Generics and Biosimilars Initiative Journal, Vol. 4, No. 3, pp. 125 - 135, May, 2015

• Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016-09)

  M. Ermisch, A. Bucsics, P. Vella Bonanno, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Digene, J. Furst, K. Garuoliene, M. van der Graff, J. Gulbinovic, A. Haycox, J. Jones, R. Joppi, O. Laius, I. Langner, A. Martin, V. Marković Peković, L. McCullagh, E. Magnusson, E. Nilsen, G. Selke, C. Sermet, S. Simoens, R. Sauremann, A. Schuurman, R. Ramos, V. Vlahović-Palčevski, C. Zara, B. Godman, Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways, Frontiers in Pharmacology, Vol. 7, pp. 1 - 9, Sep, 2016

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021